ecancermedicalscience

Research

Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: modulation by tetrathiomolybdate, KRAS/BRAF mutations and c-MYC/p53 status

8 Jan 2019
Ali Calderon-Aparicio, Alejandro Cornejo, Andrea Orue, Manuel Rieber

Ammonium tetrathiomolybdate (TTM) and disulfiram (DSF) are copper (Cu) chelators in cancer clinical trials partly because Cu chelation: a) restricts the activity of Cu-binding MEK1/2 enzymes which drive tumourigenesis by KRAS or BRAF oncogenic mutations and b) enhances uptake of oxaliplatin (OxPt), clinically used in advanced KRAS-mutant colorectal carcinomas (CRC). Whereas TTM decreases intracellular Cu trafficking, DSF can reach other Cu-dependent intracellular proteins. Since the use of individual or combined Cu chelation may help or interfere with anti-cancer therapy, this study investigated whether TTM modifies the response to DSF supplemented with: 1) UO126, a known MEK1/2 inhibitor; 2) other Cu chelators like neocuproine (NC) or 1, 10-o-phenanthroline (OPT) in wt p53 melanoma cells differing in BRAF or KRAS mutations; 3) OxPt in mutant p53 CRC cells devoid of KRAS and BRAF mutations or harbouring either KRAS or BRAF mutations. TTM was not toxic against V600E-mut-BRAF A375 and G12D-mut-KRAS/high c-myc C8161 melanoma cells. Moreover, TTM protected both melanoma types from toxicity induced by DSF, NC and co-treatment with sub-lethal levels of DSF and the MEK inhibitor, UO126. Toxicity by co-treatment with DSF OPT was poorly reversed by TTM in C8161 melanoma cells. In contrast to the greater toxicity of 0.1 μM DSF against mutant p53 CRC cells irrespective of their KRAS mutation, TTM did not protect G12V-mut-KRAS/high c-myc SW620 CRC from DSF OxPt compared to KRAS-WT/BRAF-WT Caco-2 CRC. Our results show that DSF co-treatment with: a) MEK inhibitors may enhance tumour suppression; b) OxPt in CRC may counteract impaired response to cetuximab by KRAS/BRAF mutations and c) as a single treatment, TTM may be less effective than DSF and decreases the efficacy of the latter.

Highlights

(a) Potentiation of melanoma antitumour toxicity of DSF by MEK inhibitor is reversed by TTM.

(b) KRAS/c-MYC dysregulation attenuates TTM reversion of melanoma toxicity by DSF OPT.

(c) KRAS/c-MYC dysregulation increases melanoma NC toxicity reversed by TTM.

(d) BRAF mutation and lower c-MYC may attenuate toxicity by DSF ± OxPt in colorectal cancer cells.

Article metrics: 1213 views
573
640

Related Articles

Luis Larrea, Enrique López, Paola Antonini, Verónica González, Miguel Ángel Berenguer, Maria Carmen Baños, Jose Bea, Jose Domingo
Rachel P Riechelmann, Renata D’Alpino Peixoto, Gustavo Dos Santos Fernandes, Rui F Weschenfelder, Gabriel Prolla, Duilio Rocha Filho, Aline Chaves Andrade, Marcela Crosara, Juliana Florinda M Rego, Rene C Gansl, Felipe Coimbra, Samuel Aguiar Jr, Elisângela Carvalho, Paulo M Hoff, Anelisa K Coutinho
Ryan M Kahn, Sushmita Gordhandas, Kiersten Craig, Tanaka K Dune, Kevin Holcomb, Eloise Chapman-Davis, Melissa K Frey
Frederic Ivan Ting, Danielle Benedict Sacdalan, Honey Sarita Abarquez, Arnold John Uson